Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma

Malignant mesotheliomas frequently harbor loss of CDK2NA which is associated with shorter survival and may represent a novel treatment strategy for these patients. Dean A. Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, presents findings of a Phase II study investigating the efficacy of abemaciclib, a CDK4/6 inhibitor in patients with p16ink4a negative relapsed mesothelioma in the MiST2 study (NCT03654833). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.